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ABSTRACT
Objectives: A substantial proportion of patients have recently reported pain reduction levels of ≥80% following treatment
with Evoked Compound Action Potential (ECAP) spinal cord stimulation (SCS). The additional health-related quality of life
(HRQoL) utility gain that can be achieved in this patient group is unclear. The aim of this study is to quantify the HRQoL utility
values seen in a remission health state (defined as ≥80% pain reduction) and contrast with more traditional health states of
<50% and ≥50% pain relief.
Materials and Methods: Pain intensity assessed using a 100 mm visual analogue scale (VAS) and EQ-5D-5L questionnaires
were collected from 204 patients treated with ECAP SCS for chronic back and leg pain and followed up to 12 months. Utility
values were derived using EQ-5D-5L responses crosswalked to EQ-5D-3L. Linear regression models adjusted for baseline utility
values and patient demographics were used to compare differences in utility values across health states.
Results: Patients in the remission health state (i.e., ≥80% pain reduction) consistently reported statistically significant greater
utility values (+0.09 to +0.15, all p < 0.003) compared to patients reporting ≥50% pain relief at 3- and 12-month follow-up for
overall, back, and leg VAS pain. The gain in utility values per percent unit of pain reduction was statistically significant at 3-
and 12-month follow-up with a mean increase in HRQoL utility score between 0.003 and 0.005 observed for each percent of
pain reduction.
Conclusion: Our analyses show that patients in a remission health state report statistically and clinically significant better
HRQoL than patients experiencing lesser pain relief.
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INTRODUCTION
Health-related quality of life (HRQoL) is a commonly used out-
come measure for clinical trials. The use of HRQoL tools as part of
clinical trials allow to obtain health utility values which are used
to inform economic evaluations and determine the cost effective-
ness of an intervention. Utility values also can be assigned to
health states in economic models that consider outcomes of
importance for a specific population (1). To date, the health states
used to inform model-based economic evaluations of spinal cord
stimulation (SCS) have all considered patient experience with
optimal (i.e., ≥50%) or suboptimal (i.e., <50%) reduction in pain.
The field of neurostimulation has seen numerous advances in
recent years that include new waveforms (e.g., burst (2), high fre-
quency (3), high density) (4), new neural target areas (e.g., dorsal
root ganglion) (5), and, most recently, measurement of the neuro-
physiological response to SCS to confirm stimulation of the
intended target within the therapeutic window to modulate neu-
ral activity that drives pain inhibition (i.e., Evoked Compound
Action Potential [ECAP] SCS, closed-loop) (6). Traditionally,
satisfactory pain relief following therapy has been defined as a
reduction in pain rating of 30–50% or more. However, more
recent clinical trials of SCS have reported a substantial proportion
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of chronic pain patients reporting pain reduction levels of ≥80%
(6,7). In contrast to lower levels of pain relief, this group of “high
responders” (or “remitters”) have the potential ability to achieve
considerably better levels of HRQoL.
However, it remains unclear what the additional extent of
HRQoL utility gain might be achieved in this population. Further-
more, the cost effectiveness of newer SCS technologies may be
underestimated by not formally including consideration of addi-
tional gains in health (and reductions in costs) associated with
high responders. In addition, the probabilities of achieving differ-
ent pain reduction thresholds and associated health state utility
values has the potential to affect cost effectiveness estimates of
SCS. Empirical research is therefore needed to determine the util-
ity values associated with these pain health states to improve
existing SCS economic models.
The aim of this study is to quantify the HRQoL utility values
seen in remitters (i.e., ≥80% pain reduction) and contrast this with
the values associated with the more traditional health states of
<50% and ≥50% pain relief.
MATERIALS AND METHODS
Study Design
This study used data from a total of 204 patients from two pre-
viously reported studies (EVOKE [NCT02924129] and AVALON
[ACTRN12615000713594]) in patients with chronic back and leg
pain who received SCS using the Evoke SCS System (Saluda Medi-
cal) with follow up at 3- and 12-month postimplant. EVOKE was a
multicenter, double-blind, parallel-arm randomized controlled trial
(RCT) conducted in 13 centers in the US with 134 patients ran-
domized 1:1 to closed-loop SCS or open-loop (i.e., conventional)
SCS (6). AVALON was a multicenter, prospective single-arm study
conducted in five centers in Australia with 70 patients screened
(7). Both studies were conducted in compliance with ethical and
regulatory guidelines and were approved by local ethics commit-
tees prior to subject enrolment.
ECAP SCS
In SCS, electrodes are implanted in the epidural space over the
dorsal aspect of the spinal cord and connected to a stimulator to
deliver electrical stimulus with the goal of producing pain relief
and other clinical benefits. SCS therapies, however, are limited in
that stimulation occurs without knowledge of whether the
intended target is activated or the level of such activation (8).
They are further challenged by the constantly changing distance
between the electrode and the spinal cord that occurs with both
patient involuntary physiological and voluntary movement (9).
These factors may contribute to the variability observed in clinical
outcomes (10).
The Evoke System was designed to address these limitations by
continuously recording in vivo human spinal cord electrophysiol-
ogy to confirm modulation of neural activity that drives pain inhi-
bition (11,12). An ECAP is measured for every stimulation pulse
delivered, which reflects the type and degree of spinal cord acti-
vation elicited by SCS (see Supporting Information Material 1).
Thus, the intended target is identified and the therapy delivered
is confirmed. The system may operate in fixed-output, open-loop
(open-loop) or ECAP-controlled, closed-loop (closed-loop) mode.
ECAP measurement is performed in both modes and may be used
to determine optimal stimulation settings. In closed-loop mode,
the measured ECAP is compared to the target ECAP amplitude
and the stimulation current is automatically adjusted to maintain
consistent spinal cord activation.
Demographic and Outcome Data
For the present study, we obtained the following individual
patient data:
1. Patient demographics: age, gender, duration of pain, previous
back surgery;
2. Pain intensity: overall, back, and leg pain visual analog scale
(VAS) scores at baseline, 3- and 12-month follow-up;
3. HRQoL: EQ-5D-5L utility scores at baseline, 3- and 12-month
follow-up.
Pain intensity was assessed using a 100 mm VAS ranging from
0 (no pain) to 100 (worst possible pain) (13). The VAS is consid-
ered a reliable and valid measure of subjective phenomena
including chronic pain (13,14). Levels of pain relief were based on
the health states currently used in economic models to assess the
impact of SCS:
• “No pain relief” (NPR): no pain relief or worsening of pain;
• “Suboptimal pain relief” (SPR): pain relief up to 50%;
• “Optimal pain relief” (OPR): ≥50% pain relief.
In addition, we defined ≥80% pain relief as indicative of “high
response” or “remittance” (R) (6,15,16).
HRQoL was derived from participants’ responses to the EQ-5D-
5L instrument. The EQ-5D-5L descriptive system is a questionnaire
designed to be completed by the patient and comprising five
dimensions (mobility, self-care, usual activities, pain/discomfort,
and depression/anxiety), where each dimension has five response
levels: no problems, slight problems, moderate problems, severe
problems, unable to/ extreme problems (17). The respondent is
asked to indicate his/her overall health state by selecting the level
that corresponds to his/her quality of life for each of the five
dimensions. Responses to the EQ-5D-5L were converted into sin-
gle (utility) indices using a set of weights (tariff) reflecting popula-
tion preferences for the particular health state. Utility scores were
obtained by using the EQ-5D-5L responses crosswalked to the
EQ-5D-3L UK value set (18). Results also are presented considering
utility scores obtained using the US value set for EQ-5D-5L cross-
walk to EQ-5D-3L (see Supporting Information Material 2).
Statistical Analysis
Data on 170 patients provided 99% power at 5% alpha to
detect a clinically important difference in EQ-5D utility of 0.10
between pain cut-offs assuming a standard deviation of
0.20 (19).
Probabilities of patients achieving the four different pain
reduction thresholds (no pain relief, suboptimal pain relief,
optimal pain relief, and remission) and associated HRQoL utility
values (means and 95% confidence intervals [CIs]) were esti-
mated at each threshold for EQ-5D data at 3- and 12-month
follow-up.
Linear regression models were used to compare the differences
in utility values across the pain reduction threshold. Given the
observational nature of these analyses, models were adjusted for
baseline utility values, patient age, gender, duration of pain, and
previous back operation history. A secondary regression analysis
was undertaken using pain reduction as a continuous variable. All
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models were run separately for EQ-5D utilities at 3- and 12-month
follow-up data and for overall, leg, and back pain.
All data analyses were undertaken using STATA v16.0.
RESULTS
Between August 2015 and September 2016 (AVALON case
series, n = 70) and January 2017 and January 2018 (EVOKE RCT,
n = 134), a total of 204 patients were enrolled in the respective
studies (Fig. 1). The 12-month follow-up assessment was com-
pleted by a total of 146 patients across both studies.
Participants in the studies had an average age of 55.6 years and
relatively equal representation by sex, with a mean overall VAS pain
of 81.3 and primarily a failed back surgery syndrome diagnosis
(Table 1). The mean utility value with EQ-5D at baseline was 0.33.
At 3- and 12-month follow-up more than half of the patients
experienced ≥80% pain relief (i.e., remission) for overall, back, and
leg pain (Table 2). Optimal pain relief (i.e., ≥50% and <80%) was
experienced by approximately a quarter of patients across the types
of pain and follow-ups. Suboptimal pain relief (i.e., <50%) was
achieved by between 11% and 21% of patients across the types of
pain and follow-ups. Only a small number of patients (i.e., between
1% and 3%) did not obtain some degree of pain relief.
The mean (SD) utility values derived from the EQ-5D were 0.67
(0.20) at 3-month follow-up 0.65 (0.22) at 12-month follow-up.
Comparison of utility values derived from the EQ-5D between
NPR and SPR health states shows no statistically significant
3
Figure 1. Study flow diagram.
Table 1. Population Characteristics at Baseline.
Characteristic N = 204
Data source
EVOKE trial—N (%) 134 (66%)
AVALON study—N (%) 70 (34%)




Duration of pain (years)—mean (SD) 13.0 (10.2)
Previous back surgery—N (%) 128 (63%)




EQ-5D utility (UK values)—mean (SD) 0.33 (0.23)
SD, standard deviation; VAS, visual analog scale.
Neuromodulation 2020; ••: ••–••© 2020 The Authors. Neuromodulation: Technology at the Neural Interface
published by Wiley Periodicals LLC on behalf of International Neuromodulation Society.
www.neuromodulationjournal.com
HRQoL GAINS IN CHRONIC NEUROPATHIC PAIN AFTER SCS
differences for overall and back pain at 3- or 12-month follow-up
(Table 3). A statistically significant difference is observed for NPR
versus SPR for leg VAS pain at 12-month follow-up. Comparison
of SPR versus OPR health states shows statistically significant
greater utility scores for OPR health state at 3- and 12-month
follow-up for overall and back VAS pain and at 12 months only
for leg VAS pain. Patients in the R health state consistently
reported statistically significant greater utility values than patients
in the OPR health state at 3- and 12-month follow-up for overall,
back, and leg VAS pain.
The gain in utility values per percent unit of pain reduction was
statistically significant at 3- and 12-month follow-up for overall,
back, and leg VAS pain (Table 4). A mean increase in HRQoL utility
score between 0.003 and 0.005 is observed for each percent of
pain reduction experienced in overall, back, or leg VAS pain. The
r2, which explains the variance in utility score due to pain relief
observed, ranged from 0.25 (leg VAS pain at 3 months) to 0.42
(back VAS pain at 12 months).
Positive correlation coefficients between EQ-5D-5L utility values
and pain reduction in overall VAS pain were 0.667 and 0.550 at
3-month follow-up (Fig. 2) and 12-month follow-up (Fig. 3),
respectively. Similar correlation coefficient values were observed
for back (0.613, 0.604) and leg (0.654, 0.500) VAS pain at 3- and
12-month follow-up, respectively.
Utility values derived from the EQ-5D-5L responses
crosswalked to EQ-5D-3L US value set show greater index
scores for all the different health states (Supporting Informa-
tion Material 2). Differences between health states observed
using the US value set are consistent with the results based on
the UK value set.
DISCUSSION
This study shows that the improvement in HRQoL utility of peo-
ple with chronic pain is directly associated with their level of pain
relief. Our results confirm that a “high response” or “remission”
health state (i.e., ≥80% pain relief) is associated with greater
HRQoL utility when compared with the more traditional level of
≥50% pain relief. We found a mean gain +0.09 to +0.15 on EQ-5D
in utility associated with the remission health state compared to
≥50% pain relief. This gain was both statistically significant and
clinically important (i.e., >0.074) (20). The data and HRQoL utility
values were derived from studies with ECAP SCS. Future studies
of SCS in particular and other chronic pain treatments in general
need to evaluate if similar utility gains are obtained for these
health states mainly the remission health state.
The health states considered for this study reflect those used in
previous economic models to assess the cost-effectiveness of SCS.
The mean index score observed at baseline (i.e., 0.33) corresponds
to that previously reported for patients with severe chronic pain
with neuropathic characteristics (21). The HRQoL utility values for
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Table 2. Level of Pain Relief by Health States at 3- and 12-Month Follow-Up.
Overall pain n/N (%) Back pain n/N (%) Leg pain n/N (%)
3-month 12-month 3-month 12-month 3-month 12-month
No pain relief (0%) 2 (1%) 2 (1%) 2 (1%) 4 (3%) 4 (3%) 3 (2%)
Suboptimal pain relief (<50%) 28 (18%) 19 (13%) 33 (21%) 24 (17%) 17 (11%) 18 (13%)
Optimal pain relief (≥50% to 80%) 44 (28%) 44 (30%) 38 (25%) 39 (27%) 32 (22%) 32 (23%)
Remission (≥80%) 82 (53%) 81 (55%) 82 (53%) 78 (54%) 95 (64%) 85 (62%)
Total 156 146 155 145 148 138
Table 3. Levels of EQ-5D Utility (UK Values) by Health State at 3- and 12-Month Follow-Up.
Mean utility score (95% CI) Comparison of health states Mean utility score (95% CI) Comparison of health states
3-month Contrasts p value* 12-months Contrasts p value*
Overall VAS pain
No pain relief (NPR) 0.42 (−2.28 to 3.12) - - 0.14 (−1.91 to 2.20) - -
Suboptimal pain relief (SPR) 0.50 (0.42–0.58) NPR vs. SPR 0.425 0.43 (0.31–0.55) NPR vs. SPR 0.149
Optimal pain relief (OPR) 0.63 (0.57–0.68) SPR vs. OPR 0.004 0.62 (0.57–0.68) SPR vs. OPR <0.0001
Remission (R) 0.77 (0.73–0.80) OPR vs. R <0.0001 0.73 (0.69–0.77) OPR vs. R <0.0001
Back VAS pain
No pain relief (NPR) 0.42 (−2.28 to 3.12) - - 0.32 (0.20–0.44) - -
Suboptimal pain relief (SPR) 0.52 (0.44–0.59) NPR vs. SPR 0.395 0.42 (0.32–0.53) NPR vs. SPR 0.481
Optimal pain relief (OPR) 0.62 (0.57–0.68) SPR vs. OPR 0.002 0.65 (0.60–0.69) SPR vs. OPR <0.0001
Remission (R) 0.77 (0.73–0.80) OPR vs. R <0.0001 0.74 (0.70–0.78) OPR vs. R <0.0001
Leg VAS pain
No pain relief (NPR) 0.37 (0.07–0.67) - - 0.08 (−0.25 to 0.41) - -
Suboptimal pain relief (SPR) 0.49 (0.35–0.64) NPR vs. SPR 0.484 0.49 (0.37–0.61) NPR vs. SPR <0.001
Optimal pain relief (OPR) 0.63 (0.57–0.69) SPR vs. OPR 0.343 0.58 (0.51–0.64) SPR vs. OPR <0.0001
Remission (R) 0.74 (0.70–0.77) OPR vs. R <0.003 0.72 (0.68–0.76) OPR vs. R <0.0001
*Adjusted for baseline EQ-5D utility score, age, gender, pain duration, previous back surgery.
CIs, confidence intervals; VAS, visual analog scale.
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the optimal pain relief health state observed in this study are in
line with previously reported utility values employed in economic
models of SCS, that is, 0.60 (22–24). However, the index scores
observed in this study for the no pain relief health state ranged
from 0.08 (leg VAS pain at 12-month follow-up) to 0.42 (overall
and back VAS pain at 3-month follow-up). While the value of 0.08
is in line with index scores previously reported (i.e., 0.17), the
value of 0.42 is substantially greater. This variance is likely due to
the very limited number of patients (<5%) that did not experience
any pain relief in this study as all patients received SCS. Previous
assessments of HRQoL associated with health states include
patients receiving usual care, hence likely to have a larger propor-
tion of patients with no perceived pain reduction (25).
The mean utility score observed for the remission health state
ranged between 0.72 and 0.74 at 12-month follow-up, only
slightly lower than the mean utility score of 0.79 reported for a
UK general population (21). The proportion of patients reporting
≥80% pain relief at 12-month follow-up ranged from 54% to 62%.
Closed-loop SCS was associated with 15–19% higher remission
rates compared to open-loop SCS at 3- and 12-month follow-up,
respectively (6). The proportion of patients with ≥80% pain relief
was first reported in the 2007 PROCESS trial comparing SCS using
traditional parameters to conventional medical management
where 22% of SCS subjects achieved this level of VAS leg pain
relief at 6 months (19). A recent retrospective analysis found 22%
of patients with SCS using traditional parameters had >80% pain
relief on the Numeric Rating Scale (NRS) at 12-month follow-up
(20% of patients with NRS = 0) (15). Another retrospective analysis
examined remission defined as a VAS back pain score ≤ 3.0 cm
for at least 6 months and reported 55% of patients with high fre-
quency SCS in remission at 24-month follow-up (16). The same
study observed that a subject in remission at 12 months was 8.1
times more likely to be in remission at 24 months than a patient
who was not (odds ratio = 8.1, 95% CI = 3.7–17.4). As was
observed with ECAP SCS in the current study, higher remission
rates have been observed with newer SCS models and thus it is
important to consider this in economic models of cost effective-
ness for these new technologies.
The utility scores for the different health states varied consider-
ing the use of EQ-5D UK or US value set. The instrument and
value set used to derive utility scores should be clearly reported.
As previously reported, the choice between EQ-5D and other
HRQoL tools such as the SF-6D can result in large differences in
the estimation of utility scores for chronic pain (21). Previous stud-
ies have reported differences between EQ-5D specific country tar-
iffs among type 2 diabetes patients (26), Crohn’s disease (27), or
5
Table 4. Levels of EQ-5D Utility (UK Values) at 3- and 12-Month Follow-Up by Pain Relief as a Continuous Variable.
Mean change in utility per percent unit of pain relief change
Univariable analysis Multivariable analysis*
Mean 95% CI p value Mean 95% CI p value
3-month
Overall pain 0.004 0.003–0.005 <0.0001 0.005 0.004–0.006 <0.0001
Back pain 0.004 0.003–0.005 <0.0001 0.004 0.003–0.005 <0.0001
Leg pain 0.003 0.002–0.004 <0.0001 0.003 0.002–0.004 <0.0001
12-month
Overall pain 0.005 0.004–0.006 <0.0001 0.005 0.004–0.006 <0.0001
Back pain 0.004 0.003–0.005 <0.0001 0.004 0.003–0.005 <0.0001
Leg pain 0.004 0.003–0.005 <0.0001 0.004 0.003–0.005 <0.0001
*Adjusted for baseline EQ-5D utility score, age, gender, pain duration, previous back surgery.
Figure 2. Univariable relationship between EQ-5D utility (UK values) at
3-month follow-up versus percent overall pain relief. [Color figure can be
viewed at wileyonlinelibrary.com]
Figure 3. Univariable relationship between EQ-5D utility (UK values) at
12-month follow-up versus percent overall pain relief. [Color figure can be
viewed at wileyonlinelibrary.com]
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general population (28) but not for patients with HIV (29). There is
evidence that SF-6D preference weights differ between countries.
Comparisons between SF-6D value sets for UK and US (30), Hong
Kong (31), Japan (32), and Portugal (33) suggest important differ-
ences in valuation. Utility scores derived from different instru-
ments or considering different countries preference weights
should not be used interchangeably with risk of impacting
funding decisions.
It is unclear how the differences between the utility scores
derived from EQ-5D value sets would impact an economic evalua-
tion. Since the utility values are applied to both treatments and
their comparators, to some extent the differences may be even
including the incremental gain associated with an intervention
(34). While several model-based economic evaluations of SCS
have been published (35), the impact of using different value sets
and adding a remission health state needs to be further
investigated.
Strengths and Weaknesses
We believe this to be the first empirical study to analyze and
quantify the impact of remission on HRQoL. Analyses conducted
considered index scores derived from the EQ-5D employing pref-
erence weights for both the UK and US. Our findings were consis-
tent across pain locations and follow-up timings. Our study
population is reflective of other trial populations that included
people with chronic pain.
However, we recognize that there are potential limitations. First,
as this was an observational comparison of utility values across
pain relief states, our findings may be subject to confounding and
selection bias. However, we sought to minimize such bias by
undertaking multivariable analysis adjusting for key patient demo-
graphics and baseline utility scores that may differ across health
states. Second, the minimally clinical important difference for the
EQ-5D has been reported to be 0.074 (20). We used a conserva-
tive approach to determine the sample size required for this study
by using a difference of 0.1 between pain thresholds; a larger dif-
ference than that observed specifically for people with chronic
pain with neuropathic characteristics (i.e., 0.09 mean difference
between mild and moderate neuropathic pain) (21). Although the
number of patients included in the study were sufficient to detect
an important difference in HRQoL utility scores, the number of
patients with no pain relief were insufficient to produce reliable
findings for the no pain relief health state. We would therefore
recommend that researchers continue to use existing utility
values for the no pain relief state. Third, other definitions of remis-
sion have been proposed such as maintenance of a VAS pain
score ≤ 3.0 cm for at least 6 months (16). However, in order to
inform future economic evaluations of SCS, we specifically choose
a definition based on percentage of pain relief as this aligns with
the structure of existing models. Finally, the EVOKE and AVALON
trials used strict eligibility criteria. It is important to evaluate if the
results presented within this study are observed in routine clinical
practice.
Implications for Practice
The findings of this study have important implications for
future cost-effectiveness analyses and reporting of clinical trials in
the field of chronic pain. Reflective of technological innovations in
the therapy, a number of recent SCS clinical trials have reported
increased proportion of patients reporting higher rates of pain
relief. The EVOKE and AVALON trials (data used in this analysis)
have reported 56% and 54%, respectively, of participants with
closed-loop therapy experiencing ≥80% pain relief at 12-month
follow-up (6,7). Based on our findings, we would recommend that
economic models of chronic pain be updated to include the
remission health state. By doing so, future economic evaluations
will more appropriately capture the health gains and cost-
effectiveness of interventions.
Health states based on levels of pain relief also align with
IMMPACT recommendations for studies of chronic pain
populations to report the proportions of patients achieving mod-
erate clinically important changes (i.e., ≥30%) and substantial clin-
ically important changes (i.e., ≥50%) (36). We propose that future
studies also report the proportion of patients in remission, that is,
reporting ≥80% pain relief.
In conclusion, this study shows that the improvement in HRQoL
utility of people with chronic pain treated with ECAP SCS is
directly associated with their level of pain relief. Patients in a
remission health state defined as ≥80% pain relief report statisti-
cally and clinically significant better HRQoL when compared with
more traditional levels of pain relief of ≥50%. Based on our find-
ings, we would recommend that future clinical trials consistently
include the reporting of participants who experience ≥80% pain
relief and that economic models of chronic pain be updated to
include the remission health state.
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COMMENTS
This is an interesting piece of work that clearly demonstrates the
link between improvements in Health-related Quality of Life (HRQoL)
and its association with the level of pain relief. These facts will be of




This manuscript uses the combined population of subjects rec-
ruited to two clinical trials in Australia and USA and looks at the rela-
tionship between responder rates as judged by pain score
percentage change with that of the EQ5D-5L, a measure of Health
related quality of life. We are used to looking at responder rates of
30 or 50% pain reduction but since more than half of the subjects
treated in these trials achieved 80% reduction, it is important to see
if the correlation between responder rate and utility score continues.
The authors opine that future studies should report those patients
with greater than 80% pain reduction and that economic models
providing the cost effectiveness data be upgraded. The added utility
score difference can have a profound influence on the cost effective-
ness of the newer generation of SCS therapies.
Simon Thomson, MBBS
Basildon, Essex United Kingdom
***
The result of this study is not surprising to me - more pain relief
leads to more quality of life improvement. Intrinsically, this seems
likely to me until such time as the quality of life has approximated
the normal population. I am unsure at this time what is the best defi-
nition of remission/remitter status. Is it VAS<3 as promoted by
Amirdelfan et al., or is it >80% pain reduction from baseline? I think
the jury is out on that one and we need more nuanced studies to
answer that question. Probably both are valid if I have a stab at it.
Figure 3 is instructional. Setting aside one outlier at 30% pain relief,
one needs a minimum of 60% pain relief to see a Utility Score of 0.75
or greater. It is not all about percentage pain relief - 2/3rds of the
remission (>80% pain relief) group had a Utility Score less than 0.75. So
more factors are at play here. I would posit that extended walking dis-
tance, full wean from opioids and minimal device interaction/attention
time are additional factors that play into a very high quality of life out-
come. I believe we need to understand the significant components
that go into a high quality of life score and then tune our therapies to
deliver those outcomes. Only then can we say we have truly gone
beyond the VAS in our delivery of care. This is not a dry, dusty and
pointless field of esoteric research. It is a rich vein of understanding
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how we can connect meaningfully with our patients and improve their
lives holistically. I echo the authors’ call for additional outcome states to




This study used data of patients from two previously reported
studies in patients with back and leg pain who received an ECAP
SCS system. The study demonstrated that patients in a remission
state (pain relief >80%) reported statistically and clinically significant
better health-related quality of life (HRQoL).
Michael E. Harned, MD
Lexington, KY USA
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